About our drug discovery resource

MRC Technology’s Centre for Therapeutics Discovery (CTD) is responsible for initiating drug discovery projects against early stage emerging from academic research, for indications where there is a clear unmet need. It de-risks these targets by delivering potent and selective lead compounds or antibodies with demonstrable efficacy in a relevant disease model, ready for partnering with industry.

We have over 70 scientists

Many of our scientists come from pharmaceutical backgrounds and have experience running and delivering successful drug discovery projects to industry standard. Our expertise covers:

  • Assay development
  • Small molecule libraries
  • Structural biology / in silico screening
  • High-throughput screening
  • Medicinal chemistry
  • Antibody humanisation
  • Antibody engineering
  • Pharmacology

CTD consists of three teams


The Biology department supports projects where the aim is to generate a small molecule drug rather than a therapeutic antibody. They work closely with the Chemistry department, and are divided into two sections; Assay Development and Screening, and Compound Profiling and Cellular Pharmacology.


The Chemistry department is responsible for the synthesis and delivery of novel chemical substances that are stepping stones on the path to developing new drugs.


The BioTherapeutics team uses patented techniques to generate therapeutic antibodies, and carry out affinity maturation and biophysical characterisation. They also offer a commercial antibody humanisation service, you can find more information about the service here.

Our people

Justin Bryans is our Director of Drug Discovery, and he is supported by:

Katy Kettleborough (Associate Director, Biology)

Andy Merritt (Associate Director, Chemistry)

David Matthews (Associate Director, BioTherapeutics).

To contact them, please visit the Our People page.

Our publications and posters

Our posters and publications can be found on F1000Research.


Contains 100,000+ highly diverse compounds, with potential to access 120,000+ more through our collaborations with industry.

We have kinase and ion-channel focused compounds in our collection, as well as fragments, natural products and protein-protein interaction collections.

If you are a researcher and interested in getting access to our compound library, please contact our BD team.